Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alx Oncology Holdings Inc
(NQ:
ALXO
)
16.62
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alx Oncology Holdings Inc
< Previous
1
2
Next >
ALX Oncology Appoints Scott Garland to its Board of Directors
November 29, 2022
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
November 08, 2022
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
November 03, 2022
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Upcoming Investor Conference Participation
November 02, 2022
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
October 31, 2022
Expects to extend cash runway to mid-2025
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
ALX Oncology
Via
GlobeNewswire
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
January 20, 2022
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
October 05, 2021
From
Zymeworks Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.